global-journal-of-medical-research-b-pharma-drug-discovery-toxicology-medicine Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine 0975-5888 2249-4618 Global Journals Publishing Group Incorporated 75051 Effect of Daily Treatment with Tadalafil on Serum Prorenin, Nephrin, Plasminogen Activator Inhibitor-1 and Interleukin-6 Levels in Type 2Diabetics in Relation to Microalbuminuria AliShatha H. IRAQ, college of pharmacy -university of Baghdad- 29 09 2012 12 9 9 18

Tadalafil is a phosphodiesterase-5(PDE-5) inhibitor, currently marketed for treating erectile dysfunction, as well as, for the treatment of pulmonary arterial hypertension.These are orally available drugs acting via intracellular signaling pathways, specifically the cyclic nucleotide monophosphate cyclic GMP, represents an important mediator in controlling of the outflow in region (kidney). The use of phosphodiesterase (PDE) inhibitor-5, tadalafil, is known to restrain the degradation of cyclic GMP, could offers a great opportunities in the treatment of kidney dysfunction associated with diabetes .Which may be assessed by testing for microalbuminuria that mostly precedes the development of overt diabetic nephropathy.

 Tadalafil diabetic nephropathy prorenin nephrine interleukin-6 plasminogen activator inhibitor-1 microalbuminuria. Full Text

Tadalafil is a phosphodiesterase-5(PDE-5) inhibitor, currently marketed for treating erectile dysfunction, as well as, for the treatment of pulmonary arterial hypertension.These are orally available drugs acting via intracellular signaling pathways, specifically the cyclic nucleotide monophosphate cyclic GMP, represents an important mediator in controlling of the outflow in region (kidney). The use of phosphodiesterase (PDE) inhibitor-5, tadalafil, is known to restrain the degradation of cyclic GMP, could offers a great opportunities in the treatment of kidney dysfunction associated with diabetes .Which may be assessed by testing for microalbuminuria that mostly precedes the development of overt diabetic nephropathy.